ABPI forges five year partnership with AHSN focused on increased uptake of transformative biomedical innovations into the NHS

pharmafile | September 21, 2018 | News story | Medical Communications ABPI, NHS, UK, ahsn, collaboration 

The Association of the British Pharmaceutical Industry (ABPI) has announced that it is forging a five year partnership with the Academic Health Science Network in an effort to increase the uptake of new and innovative medicines by the NHS.

The two groups intend to increase collaboration between member companies in order to accelerate the spread of proven innovation in the UK’s National Health Service (NHS).

Mike Thompson, Chief Executive of the ABPI commented: “As a result of this new partnership, patients will be able to benefit from the innovative medicines and technologies of the future faster and more consistently. I’m delighted to be working with the AHSN Network on this important initiative. The prize for success will be a virtuous circle that delivers benefits for patients and the NHS. There will also be economic benefits to the UK from a thriving life sciences ecosystem.”

The collaborative projects will address the new national priority areas of the AHSN Network. These include; economic growth, digital and artificial intelligence, research, genomics and personalised medicine, diagnostics and medicines optimisation.

Professor Mike Hannay, Chair of the AHSN Network added: “We are excited about the opportunities afforded by our new partnership with the ABPI, with whom we already have a long-standing and very positive relationship. The AHSN Network is committed to creating the right environment for industry to work with the health and social care system. The establishment of the Innovation Exchange model, commissioned by the Office for Life Sciences, provides a step change opportunity to re-engineer a more effective industry interface. This, together with the ABPI partnership, will enable companies to benefit from a consistent offering from whichever AHSN they interact with. In turn, the NHS will benefit from better identification of products and services that can benefit patients and the health system, as well as improved signposting to relevant agencies and programmes where not directly provided by AHSNs.”

Louis Goss

Related Content


NHS given guidance on offering genetic testing to stroke patients

The NHS has been given draft guidance on offering gene tests to patients who have …

NICE recommends Hepcludex for NHS use to treat aggressive form of viral hepatitis

The National Institute for Health and Care Excellence (NICE) has recommended Hepcludex (bulevirtide) for the …


NHS in Scotland makes rheumatoid arthritis drug available

The Scottish Medicines Consortium (SMC) have recommended the use of Galapagos UK’s JYSELECA® (filgotinib) for …

Latest content